GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications ...
(PR-inside.com) Oral GLP-1 market projected to expand from $5.1 billion in 2026 to $89 billion in 2034 Novo announces additional weight-loss in patients switching from injected to oral delivery KELOWNA, BC / ACCESS Newswire / October 6, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a globa…
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


